Last reviewed 2026-04-23 · How we verify

CAN-2409

CAN-2409 is a T-cell engager that targets the CD3 component of the T-cell receptor.

CAN-2409 is a T-cell engager that targets the CD3 component of the T-cell receptor. Used for Metastatic solid tumors.

At a glance

Mechanism of action

It works by binding to CD3 on T-cells and recruiting them to the tumor microenvironment, where they can recognize and kill cancer cells. This approach allows for a targeted and sustained activation of T-cells, potentially leading to improved anti-tumor responses.

Approved indications

• Metastatic solid tumors

Common side effects

• Fatigue
• Nausea
• Diarrhea

Key clinical trials

• A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec (PHASE2)
• CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC (PHASE2)
• Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) (PHASE2)
• Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer (PHASE3)
• Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer (PHASE1)
• Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma (PHASE2)
• Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• CAN-2409 CI brief — competitive landscape report
• CAN-2409 updates RSS · CI watch RSS
• Candel Therapeutics, Inc. portfolio CI